Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Luke

Showing results (11-20 of 422) with videos related to

Pageof 43
Sort By:
Early Childhood Education Journal|June 26, 2023
"Treat Them Like Human Beings": Black Children's Experiences with Racial Microaggressions in Early Childhood Education During COVID-19Idara Essien, J Luke Wood
Emerging Infectious Diseases|February 24, 2006
Vaccines for pandemic influenzaCatherine J Luke, Kanta Subbarao
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment ResponseChristopher S Garris, Jason J Luke
Oncotarget|February 17, 2015
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanomaJason J Luke, Patrick A Ott
Cancer|December 24, 2019
Considering adjuvant therapy for stage II melanomaAndrew S Poklepovic, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2023
Myeloid Maturity: ATRA to Enhance Anti-PD-1?Daniel J Olson, Jason J Luke
Pharmacological Research|March 22, 2017
Mechanistic and pharmacologic insights on immune checkpoint inhibitorsRandy F Sweis, Jason J Luke
The Oncologist|May 28, 2013
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaJason J Luke, F Stephen Hodi
Missouri Medicine|January 24, 2008
Treatment options for the common wartJ Luke Welch, Karen E Edison
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2011
Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanomaJason J Luke, F Stephen Hodi
Pageof 43

Showing results (11-20 of 422) with videos related to

Sort By:
Pageof 43
Early Childhood Education Journal|June 26, 2023
"Treat Them Like Human Beings": Black Children's Experiences with Racial Microaggressions in Early Childhood Education During COVID-19Idara Essien, J Luke Wood
Emerging Infectious Diseases|February 24, 2006
Vaccines for pandemic influenzaCatherine J Luke, Kanta Subbarao
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment ResponseChristopher S Garris, Jason J Luke
Oncotarget|February 17, 2015
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanomaJason J Luke, Patrick A Ott
Cancer|December 24, 2019
Considering adjuvant therapy for stage II melanomaAndrew S Poklepovic, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2023
Myeloid Maturity: ATRA to Enhance Anti-PD-1?Daniel J Olson, Jason J Luke
Pharmacological Research|March 22, 2017
Mechanistic and pharmacologic insights on immune checkpoint inhibitorsRandy F Sweis, Jason J Luke
The Oncologist|May 28, 2013
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaJason J Luke, F Stephen Hodi
Missouri Medicine|January 24, 2008
Treatment options for the common wartJ Luke Welch, Karen E Edison
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2011
Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanomaJason J Luke, F Stephen Hodi
Pageof 43